Related Experiment Video

Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell

Evgenii Shumilov1, Rebecca Wurm-Kuczera2, Joseph Kauer3

  • 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster.

Haematologica
|April 2, 2026
PubMed

Abstract:

Not available.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Cytotherapy·2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Haematologica·2026

AI for prognostic assessment of diffuse large B-cell lymphoma using H&E whole-slide images.

HemaSphere·2026

A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.

Blood advances·2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Haematologica·2026

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

British journal of haematology·2026

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Haematologica·2026

Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia".

Haematologica·2026

Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

Haematologica·2026

Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis.

Haematologica·2026

Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: "First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level".

Haematologica·2026

Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients.

Haematologica·2026

Inflammation-coagulation biomarkers predict catheter-related thrombosis following peripherally inserted central catheter placement in patients with hematologic malignancies: a retrospective cohort study.

Translational cancer research·2026

Post-traumatic Blaschko-linear dermatitis following prostatectomy: a rare case report.

Annals of medicine and surgery (2012)·2026

Mast cell leukemia with complex genomic alterations in an elderly patient with prior hematologic and solid malignancies: a case report.

Annals of medicine and surgery (2012)·2026

Early Versus Delayed Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis: A Systematic Review.

Cureus·2026

Primary Pleural Epithelioid Angiosarcoma Presenting with Recurrent Haemorrhagic Pleural Effusions.

European journal of case reports in internal medicine·2026

Diffuse high-grade glioma with gliomatosis cerebri pattern mimicking symmetric white matter disease.

Radiology case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us